Verastem (VSTM) Cantor Global Healthcare Conference 2025 summary

Key product approvals and clinical progress

• Achieved first approval for a novel combination therapy in low-grade serous ovarian cancer, marking the first such approval for this indication and the first dual novel oncology approval.

• Early launch generated $2.1 million in revenue in six weeks, with expansion to three specialty distributors and GPO contracts now in place.

• Peer-reviewed publications enabled application for NCCN guideline inclusion for KRAS wild type, with review set for October.

• Confirmatory Phase 3 (RAMP 301) enrollment expected to complete by year-end, with sample size re-estimation in Q4.

• Investigator-sponsored front-line study underway at Memorial Sloan Kettering, aiming for future front-line label expansion.

Mechanism of action and clinical rationale

• Avutametnib is a dual RAF/MEK inhibitor, overcoming feedback activation seen with MEK-only inhibition.

• FAK inhibition broadens pathway suppression and may enhance efficacy of both avutametnib and newer KRAS inhibitors.

• Combination targets both vertical and horizontal signaling, maximizing pathway blockade with two agents.

Market access, reimbursement, and uptake

• Specialty distributors and GPO contracts now enable broad market servicing, including large practices and community settings.

• Peer-reviewed data and NCCN guideline inclusion are key for reimbursement and physician adoption.

• Usage observed in both KRAS mutant and wild type patients, with reimbursement achieved for both.

• Uptake is broad, with prescriptions from both centers of excellence and community physicians.

• Zero copay program and minimal use of bridge drugs support patient access, with gross-to-net expected at 15–20%.